Marksans Pharma (BOM:524404) Accounts Payable: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524404 Marksans Pharma Ltd BOM:524404
80 GF Score
Price ₹321.25
GF Value ₹252.37
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Marksans Pharma Accounts Payable?

Marksans Pharma BOM:524404 +0.20% 80 Accounts Payable is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:524404 with a GF Score™ of 80/100 and a GF Value™ of ₹252.37 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Marksans Pharma's Accounts Payable for the quarter that ended in Jun. 2026 was ₹0 Mil.

Marksans Pharma's quarterly Accounts Payable increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹3,369 Mil) but then declined from Mar. 2026 (₹3,369 Mil) to Jun. 2026 (₹0 Mil).

Marksans Pharma's annual Accounts Payable increased from Mar. 2024 (₹2,683 Mil) to Mar. 2025 (₹3,057 Mil) and increased from Mar. 2025 (₹3,057 Mil) to Mar. 2026 (₹3,369 Mil).

Marksans Pharma Accounts Payable Related Terms

Marksans Pharma Accounts Payable Historical Data

* Premium members only.

The historical data trend for Marksans Pharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marksans Pharma Accounts Payable Chart

Marksans Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,000.79 2,306.01 2,682.77 3,056.99 3,369.09

Marksans Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2,848.15 0.00 3,369.09 0.00
BOM:524404
80GF Score
Marksans Pharma Ltd BOM:524404
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marksans Pharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹0 Mil mean?
Marksans Pharma (BOM:524404) has a Accounts Payable of ₹0 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Marksans Pharma and its competitors.
Is Marksans Pharma's Accounts Payable too high?
Marksans Pharma's current Accounts Payable is ₹0 Mil. Overall, Marksans Pharma has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's Accounts Payable compare to LLY and JNJ?
Marksans Pharma's Accounts Payable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Marksans Pharma and its competitors. Marksans Pharma's current Accounts Payable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹252.37, compared to a current price of ₹321.25 — trading 27.3% above its estimated fair value. The current Accounts Payable is ₹0 Mil. Marksans Pharma's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current Accounts Payable is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marksans Pharma (BOM:524404) Overvalued in 2026?

Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued. The current stock price of ₹321.25 is trading 27.3% above its estimated GF Value™ of ₹252.37. GuruFocus considers Marksans Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524404:

  • Accounts Payable: ₹0 Mil
  • GF Value™: ₹252.37 vs. price of ₹321.25 (27.3% above fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Marksans Pharma Business Description

Other Exchanges MARKSANS:India
Address Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
80GF Score

Get the complete analysis for BOM:524404

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹321.25
Price
₹252.37
GF Value